Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database

• Jennifer R. Brown,
• Paolo Ghia,
• Wojciech Jurczak,
• Brad S. Kahl,
• Nicole Lamanna,
• Tadeusz Robak,
• Mazyar Shadman,
• Constantine S. Tam,
• Lugui Qiu,
• Jason Paik,
• Tommi Salmi,
• Liping Wang,
• Jun Zhang,
• Meng Zhang,
• Aileen Cohen,
• Han Ma,
• Alessandra Tedeschi

Affiliations

Jennifer R. Brown

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Paolo Ghia

Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan

Wojciech Jurczak

Maria Skłodowska-Curie National Research Institute of Oncology, Kraków

Brad S. Kahl

Siteman Cancer Center, Washington University School of Medicine, St Louis, MO

Nicole Lamanna

Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY

Tadeusz Robak

Medical University of Łódź, Łódź

Mazyar Shadman

Fred Hutchinson Cancer Research Center, Seattle, WA

Constantine S. Tam

Alfred Hospital and Monash University, Melbourne, VIC

Lugui Qiu

State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Jason Paik

BeiGene USA, Inc, San Mateo, CA

Tommi Salmi

BeiGene International GmbH, Basel

Liping Wang

BeiGene (Shanghai) Co, Ltd, Shanghai

Jun Zhang

BeiGene USA, Inc, San Mateo, CA

Meng Zhang

BeiGene USA, Inc, San Mateo, CA

Aileen Cohen

BeiGene USA, Inc, San Mateo, CA

Han Ma

BeiGene USA, Inc, San Mateo, CA

Alessandra Tedeschi

ASST Grande Ospedale Metropolitano Niguarda, Milan